» » »

Cancer Drug for Alzheimer's Treatment Boone NC

New research suggests that a cancer drug might be able to restore day-to-day memory in patients with Alzheimer's disease. The disease, the most common form of dementia among the elderly, is expected to afflict 120 million people worldwide by 2050. Often the first sign is loss of short-term memory.

Jeffrey Paul Crittenden
(828) 262-0600
400 Shadowline Dr
Boone, NC
Specialty
Neurology

Data Provided by:
Jeffrey Paul Crittenden, MD
(828) 262-0600
400 Shadowline Dr Ste 202
Boone, NC
Specialties
Neurology
Gender
Male
Education
Medical School: Emory Univ Sch Of Med, Atlanta Ga 30322
Graduation Year: 1986

Data Provided by:
Suzanne Mc Adams
895 State Farm Rd
Boone, NC
Specialty
Neurology, Alzheimer's Specialist

High Country Neurology
(828) 262-0600
400 Shadowline Dr Ste 202
Boone, NC

Data Provided by:
Lori Beth Schneider, MD
(704) 896-5591
19615 Liverpool Pkwy Ste A
Cornelius, NC
Specialties
Neurology
Gender
Female
Education
Medical School: New York Univ Sch Of Med, New York Ny 10016
Graduation Year: 1990

Data Provided by:
Suzanne Elaine McAdams
(828) 264-7720
895 State Farm Rd
Boone, NC
Specialty
Neurology

Data Provided by:
Suzanne Elaine Mc Adams, MD
Banner Elk, NC
Specialties
Neurology
Gender
Female
Education
Medical School: George Washington Univ Sch Of Med & Hlth Sci, Washington Dc 20037
Graduation Year: 1990

Data Provided by:
Christopher Potter
321 Mulberry St Sw
Lenoir, NC
Specialty
Neurology, Alzheimer's Specialist

Clinton Edward Massey
(919) 731-4048
625 Country Day Rd
Goldsboro, NC
Specialty
Neurosurgery

Data Provided by:
Chunxiao Zhang, MD
(336) 716-2325
Dept Of Neurology
Winston Salem, NC
Specialties
Neurology
Gender
Female
Education
Medical School: Hebei Med Coll, Shi-Jiazhuang, Hebei, China
Graduation Year: 1987

Data Provided by:
Data Provided by:

Cancer Drug for Alzheimer's Treatment

Provided By:

TUESDAY, Sept. 8 (HealthDay News) -- New research suggests that a cancer drug might be able to restore day-to-day memory in patients with Alzheimer's disease.

The disease, the most common form of dementia among the elderly, is expected to afflict 120 million people worldwide by 2050. Often the first sign is loss of short-term memory.

"People often joke that they must have Alzheimer's because they can't remember where they put their keys, but for a person with the disease, this type of short-term memory loss is extremely debilitating," study author Ottavio Arancio, an associate professor of pathology and cell biology at Columbia University Medical Center, said in a news release.

The researchers examined a cancer drug from a family of compounds called HDAC inhibitors. The drug tinkers with DNA, and in the mice the researchers studied it appeared to make it easier for neurons in the brain to manufacture new proteins.

That process is critical in the process of recording new memories.

"Because this type of drug has already been approved for some cancer patients, we hope that clinical trials for Alzheimer's disease can start in about three to four years," said co-author Mauro Fa, an associate research scientist at Columbia.

The findings appear in the September issue of the Journal of Alzheimer's Disease.

More information

Learn more about memory from McGill University.

SOURCE: Columbia University, news release, Sept. 3, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com